Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HELPthis companyHelus Pharma Inc.	$9.28	-1.13×	0.72×	-3.74×	-0.07×	-63.2%	100.3%	317.1%	329.1%	-63.3%	-60.9%	-80.1%	0×	1.11×	0×	9.52×	0.0%	3	27.56	2	C
BETR.CNBetterLife Pharma Inc.	CA$0.22	-4.9×	-0.75×	0×	-4.53×	-113.2%	0.0%	0.0%	0.0%	15.3%	32.4%	-8.6%	-0.09×	-0.49×	-7.8×	0.03×	0.0%	3	-83.43	2	C
BNXT.CNBioNxt Solutions Inc.	CA$0.26	-10.76×	-8.07×	0×	-13.49×	-121.0%	0.0%	0.0%	0.0%	75.0%	172.2%	-6.9%	-0.63×	-0.98×	-4.2×	0.05×	0.0%	3	-88.15	2	C
LOBE.CNLobe Sciences Ltd.	CA$0.04	-1.57×	2.94×	0×	-0.32×	-29.7%	0.0%	0.0%	0.0%	-187.9%	-80.9%	-20.4%	0.12×	1.31×	-7×	3.13×	0.0%	2	-11.09	2	C
MDMA.CNPharmala Biotech Holdings Inc.	CA$0.17	-6.19×	5.47×	22.2×	-6.47×	-266.4%	-139.6%	-355.6%	-359.2%	-88.5%	-87.6%	-7.8%	0×	0.02×	0×	1.71×	0.0%	2	5.56	1	D+
MRVL.VMarvel Biosciences Corp.	CA$0.11	-3.74×	-2.07×	0×	-5.38×	-160.0%	0.0%	0.0%	0.0%	55.2%	73.6%	-13.9%	-0.58×	-1.12×	-4.66×	0.08×	0.0%	2	-56.02	2	C
Peer median	—	-4.9×	-0.75×	0×	-5.38×	-121.0%	0.0%	0.0%	0.0%	15.3%	32.4%	-8.6%	-0.09×	-0.49×	-4.66×	0.08×	0.0%	2	-56.02	2	—